Immuron Limited, an Australian-based biopharmaceutical company, has announced a positive financial outlook for the current year, projecting sales to exceed A$7 million. This marks a significant increase from the A$4.9 million achieved in the previous year. The company attributes this growth to record sales up to the end of March, continuing momentum through the Easter and ANZAC holiday periods, and the spring and summer break in North America. Immuron's Chief Executive Officer, Steven Lydeamore, highlighted that the company is on track to surpass these sales figures, underscoring a momentous rise in revenue. Additionally, Immuron's clinical product, IMM-124E (Travelan®), is anticipated to generate US$102 million in yearly revenue in the United States, based on Lumanity's opportunity assessment.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。